Chemotherapy-Induced Myelosuppression Treatment Market 2018-2028 by Top Key Players- Janssen Global Services, LLC (Johns

1. Chemotherapy-Induced Myelosuppression Treatment Market 2018-2028 by Top Key Players- Janssen Global Services, LLC (Johnson & Johnson), Partner Therapeutics, Inc. and Others Feb 2021 Report Id : REP-GB-1364 Published On : 28-Jan-2019 www.futuremarketinsights.com I Category : Healthcare, Pharmaceuticals & Medical Devices @futuremarketins I /company/future-market-insights © 2019 Future Market Insights, All Rights Reserved www.futuremarketinsights.com I @futuremarketins I /company/future-market-insights © 2019 Future Market Insights, All Rights Reserved

2. About Future Market Insights Future Market Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights,aerial view of the competitive framework,and future market trends. We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC. Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology,Healthcare, and Retail. We have a global presence with delivery centers across India specializing in providing global research reports and country research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India. We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solutionfor our client. Research Capabilities Sector Coverage             Customized Research Syndicated Research Investment Research Social Media Research Automotive and Transportation Electronics, Semiconductor, and ICT Retail and Consumer Products Industrial Automation and Equipment Chemicals & Materials Food and Beverages Services and Utilities Energy, Mining, Oil, and Gas Customized Research Subscription Information Syndicated Research For detailed subscription information please contact Hari. T (Sr. Manager - Global Business Development) Investment Research T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268 Social Media Research Email: hari.t@futuremarketinsights.com www.futuremarketinsights.com I @futuremarketins I /company/future-market-insights 2 © 2019 Future Market Insights, All Rights Reserved

3. Research Methodology (1/2) Systematic Research Approach 1 In-depth secondary research is used to ascertain overall market size, top industry players, top products, industry associations, etc. Research & Intelligence Data Collection Data Filter & Analysis Actionable Insights Business Solution Market profiling 2 FMI formulates a detailed discussion guide to conduct expert and industry interviews     Identifying key opinion leaders Questionnaire design In-depth interviews Coverage across value chain Formulating discussion guide 3 A FMI develops a list of industry players (manufacturers), distributors, retailers and industry experts Primary Research       Key industry experts Channel study Developments Market dynamics Products Conclusions Developing list of respondents B 4 FMI conducts interviews with industry experts, industry players, distributors and retailers SOLUTION Desk Research Data collection      Market participants Key strengths Product portfolio Mapping as per value chain Key focus segments C Company Analysis Data is validated by triangulation method, wherein secondary, primary and FMI analysis contribute to the final data 5 Data validation 6 Data is scrutinized using MS-Excel to obtain qualitative and quantitative insights about the industry Data analysis Primary Research# Secondary Research # Paid Publications#           Linkedin Zoominfo Salesforce Avention Company websites Company annual reports White papers Financial reports Factiva GBI Genios Meltwater 7 FMI delivers industry insights and information in the required format (PDF) Insights   # includes sources of databases www.futuremarketinsights.com I @futuremarketins I /company/future-market-insights 3 © 2019 Future Market Insights, All Rights Reserved

4. Chemotherapy-Induced Myelosuppression Treatment Market Analysis A new study by FMI reveals that the chemotherapy-induced myelosuppression treatment market is expected to grow at a subdued 3% y-o-y in 2019. Valued at nearly US$ 7 billion in 2018, gains are likely to be driven by a combination of multipronged factors, including, Development of natural product interventions for chemotherapy-induced side effects  Growing implementation of radiation treatment in cancer treatment owing to the associated high success rate of chemotherapy  Growing R&D investments in cancer research  The FMI study finds that ‘growth factor’ drugs continued to garner highest revenues in the chemotherapy-induced myelosuppression treatment market. In 2018, over 73% of the chemotherapy-induced myelosuppression treatment market revenues were consolidated in the growth factors. Gains were especially notable for granulocyte-colony stimulating factor or G-CSF, which accounted for over 60% of the global chemotherapy-induced myelosuppression treatment market revenues in 2018. www.futuremarketinsights.com I @futuremarketins I /company/future-market-insights 4 © 2019 Future Market Insights, All Rights Reserved

5. Chemotherapy-Induced Myelosuppression Treatment Market Analysis The FMI study reveals that erythropoietin-stimulating agents (ESA) also accounted for a significant market share, with revenues likely to grow at 2.8% in 2019. In April 2017, FDA announced the removal of risk evaluation and mitigation strategy (REMS) requirement for the use of ESA drugs in myelosuppression treatment. Request a Sample of this Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1364 The ESAs used in the treatment of radiation-induced myelosuppression treatment are epoetin alfa and darbepoetin alfa. This has led healthcare professionals to engage in the practice of discussing benefits as well as risks of treatments that include ESAs before initiating the use. Hematopoietic growth factors have transformed the practice of cancer treatment by allowing stimulation of production of specific cells. With this, use of thrombopoietin receptor agonists is expected to rise rapidly at the rate of 3.5% in 2019. Injectable Drugs Present Higher Therapeutic Availability over Orals The FMI study finds that injectable drugs accounted for over 97% of the chemotherapy- induced myelosuppression treatment market revenues in 2018. www.futuremarketinsights.com I @futuremarketins I /company/future-market-insights 5 © 2019 Future Market Insights, All Rights Reserved

6. Chemotherapy-Induced Myelosuppression Treatment Market Analysis The status-quo will continue in the future, however, the oral route of administration is expected to garner increasing annual revenues and expected to grow at 4.8% in 2019 over 2018. Increasing number of research validations related to the benefits of the oral route of administration can be attributed to the higher growth rate of the segment in the future. However, revenues from the injectable route of the administration continue to grow steadily on the back of their higher therapeutic availability over orally administered drugs. Market Revenues Consolidated in Neutropenia Treatment According to the study, chemotherapy-induced myelosuppression treatment market revenues heavily consolidated in the neutropenia treatment. In 2018, neutropenia indication accounted for over 62% of market revenues. As neutropenia is one of the most common side effects of chemotherapy wherein prolongation of the same can lead to life-threatening infections. Owing to the severity of the implications, chemotherapy-induced myelosuppression therapeutics are heavily used in the treatment of neutropenia. www.futuremarketinsights.com I @futuremarketins I /company/future-market-insights 6 © 2019 Future Market Insights, All Rights Reserved

7. Chemotherapy-Induced Myelosuppression Treatment Market Analysis Get Full Report Buy Now @ https://www.futuremarketinsights.com/checkout/1364 Anemia and thrombocytopenia indications also utilize chemotherapy-induced myelosuppression treatment therapeutics. The study finds that revenues in the thrombocytopenia treatment will grow at 3.7% y-o-y in 2019. Retail Pharmacies Most Prominent Sales Channel The study opines that chemotherapy-induced myelosuppression treatment therapeutics sales remain higher through retail pharmacies. Suppliers of these therapeutics have extensive distribution network with international retail pharmacies. Due to this, retail pharmacies accounted for over 48% of the chemotherapy-induced myelosuppression treatment market revenues in 2018. Owing to heavy integration of pharmacies in the hospitals, distribution of chemotherapy- induced myelosuppression treatment therapeutics through hospital pharmacies also account for a considerable share of the market revenues. The study finds that hospital pharmacies can be called the second largest distributor of chemotherapy-induced myelosuppression treatment therapeutics owing to their 45% of the market revenues. www.futuremarketinsights.com I @futuremarketins I /company/future-market-insights 7 © 2019 Future Market Insights, All Rights Reserved

8. Chemotherapy-Induced Myelosuppression Treatment Market Analysis US – The World’s Largest Chemotherapy-induced Myelosupression Treatment Market FMI reveals that North America accounted for over 82% of the revenues in chemotherapy- induced myelosuppression treatment market in 2018. Presence of leading cancer therapeutics providers, significant R&D investments and established healthcare sector contribute to the bulk of market revenues. The U.S. remains the largest consumer of the chemotherapy-induced myelosuppression treatment market. Request for Report Ask A Question @ https://www.futuremarketinsights.com/ask- question/rep-gb-1364 Market revenues in the APEJ region are likely to grow at higher rate owing to improving healthcare facility and growing penetration of advanced cancer care treatments. China, followed by India, accounts for the highest market revenues in APEJ owing to improving economic scenario and developing healthcare infrastructure. The FMI report analyses chemotherapy-induced myelosuppression treatment market for the forecast period 2018-2028. As per the report, the chemotherapy-induced myelosuppression treatment market is estimated to grow at 3.2% CAGR through 2028. www.futuremarketinsights.com I @futuremarketins I /company/future-market-insights 8 © 2019 Future Market Insights, All Rights Reserved

9. To know more about us, please visit our website: www.futuremarketinsights.com For sales queries or new topics email us on: sales@futuremarketinsights.com For media queries, contact the press office at press@futuremarketinsights.com For other queries contact: Hari. T (Sr. Manager - Global Business Development) Future Market Insights: 3rd Floor, 207 Regent Street, London W1B 3HH T: +44 20 7692 8790 | D: +44 20 3287 4268 Email: hari.t@futuremarketinsights.com Future Market Insights Global & Consulting Private Limited (FMI) Thank You www.futuremarketinsights.com I @futuremarketins I /company/future-market-insights 9 © 2019 Future Market Insights, All Rights Reserved